Compass Therapeutics (NASDAQ:CMPX) Coverage Initiated at Piper Sandler

Analysts at Piper Sandler initiated coverage on shares of Compass Therapeutics (NASDAQ:CMPX) in a research report issued on Wednesday, MarketBeat.com reports. The brokerage set an “overweight” rating and a $12.00 price target on the stock. Piper Sandler’s target price suggests a potential upside of 287.72% from the company’s current price.

CMPX has been the topic of several other reports. Leerink Partnrs lowered Compass Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Friday, November 15th. Leerink Partners downgraded Compass Therapeutics from an “outperform” rating to a “market perform” rating and dropped their target price for the stock from $5.00 to $4.00 in a report on Friday, November 15th. HC Wainwright restated a “buy” rating and issued a $10.00 price target on shares of Compass Therapeutics in a research note on Wednesday, January 8th. D. Boral Capital reiterated a “buy” rating and set a $32.00 price objective on shares of Compass Therapeutics in a research report on Wednesday, January 8th. Finally, Jefferies Financial Group upped their price target on Compass Therapeutics from $7.00 to $8.00 and gave the stock a “buy” rating in a research report on Monday, February 10th. Two investment analysts have rated the stock with a hold rating and six have issued a buy rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $11.29.

Compass Therapeutics Trading Down 8.4 %

Shares of Compass Therapeutics stock opened at $3.10 on Wednesday. The firm has a market capitalization of $425.84 million, a PE ratio of -8.36 and a beta of 1.17. The business’s 50-day moving average price is $2.40 and its 200-day moving average price is $1.86. Compass Therapeutics has a 12 month low of $0.76 and a 12 month high of $4.08.

Institutional Investors Weigh In On Compass Therapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in CMPX. Rovin Capital UT ADV purchased a new stake in shares of Compass Therapeutics in the third quarter worth approximately $25,000. Intech Investment Management LLC acquired a new stake in shares of Compass Therapeutics in the 3rd quarter worth $30,000. Tower Research Capital LLC TRC boosted its position in shares of Compass Therapeutics by 298.0% in the 4th quarter. Tower Research Capital LLC TRC now owns 17,251 shares of the company’s stock worth $25,000 after purchasing an additional 12,917 shares in the last quarter. Independent Advisor Alliance acquired a new stake in Compass Therapeutics during the 4th quarter worth about $26,000. Finally, BNP Paribas Financial Markets acquired a new stake in Compass Therapeutics during the 4th quarter worth about $27,000. 68.43% of the stock is currently owned by hedge funds and other institutional investors.

About Compass Therapeutics

Compass Therapeutics, Inc, a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells.